Acorda Therapeutics, Inc. [___] Shares Common Stock UNDERWRITING AGREEMENT dated [___], 2003 Banc of America Securities LLC Lazard Frères & Co. LLC RBC Dain Rauscher Inc.Underwriting Agreement • November 6th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
AMENDMENT No. 1 TO RUSH PAYMENTS AGREEMENTRush Payments Agreement • November 6th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT, dated as of October 27, 2003, by and between Acorda Therapeutics, Inc. (“Acorda”) and Elan Corporation, plc. (“Elan”) amends the Rush Payments Agreement effective as of September 26, 2003 (the “Payments Agreement”) by and between Acorda and Elan.
SIDE AGREEMENTSide Agreement • November 6th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
REFERENCE IS MADE to (i) the License Agreement effective as of September 26, 2003, by and between RUSH-PRESBYTERIAN-ST. LUKE’S MEDICAL CENTER, an Illinois not-for-profit corporation and having its principal office at 1725 W. Harrison St. Chicago, Ill. 60612 (“Rush”), and ACORDA THERAPEUTICS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 15 Skyline Drive, Hawthorne, New York 10532 (“Acorda”) (the “Rush/Acorda License”), and (ii) the Amended and Restated License and Supply Agreement effective as of September 26, 2003 by and between Acorda and ELAN CORPORATION, PLC., a public limited company incorporated under the laws of Ireland and having its registered office at Lincoln House, Lincoln Place, Dublin 2, Ireland (“Elan”) (the “Elan/Acorda License”). The Rush/Acorda License and the Elan/Acorda License are sometimes collectively referred to herein as the “Novation Agreements”.
AMENDMENT No. 1 TO TERMINATION AND ASSIGNMENT AGREEMENTTermination and Assignment Agreement • November 6th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT, dated as of October 27, 2003, by and among Acorda Therapeutics, Inc., (“Acorda”), MS Research & Development Corporation (“MS R & D”), Elan Corporation, plc. (“Elan”) and Elan International Services, Ltd. (“EIS”) amends the Termination and Assignment Agreement effective as of September 26, 2003 (the “Assignment Agreement”) by and among Acorda, MS R & D, Elan and EIS (collectively, the “Parties”).
